David-Dan Nguyen1, Iman Sadri1, Kyle Law1, Naeem Bhojani2, Dean S Elterman3, Ahmed S Zakaria2, Adel Arezki1, Franck Bruyère4, Luca Cindolo5, Giovanni Ferrari5, Carlos Vasquez-Lastra6, Tiago Borelli-Bovo7, Edgardo F Becher8, Hannes Cash9, Maximillian Reimann9, Enrique Rijo10, Vincent Misrai11, Kevin C Zorn12. 1. Faculty of Medicine, McGill University, Montreal, QC, Canada. 2. Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada. 3. Division of Urology, University Health Network, Toronto, ON, Canada. 4. Department of Oncology and Urology, Centre Hospitalier Universitaire de Tours, Tours, Centre-Val de Loire, France. 5. Department of Urology, Hesperia Hospital, Modena, Italy. 6. Department of Urology, ABC Medical Center, Mexico City, Mexico. 7. Borelli Urologia, Ribeirão Presto, Sao Paulo, Brazil. 8. Centro de Urologia, CDU, Buenos Aires, Argentina. 9. Department of Urology, Charite-Universitaetsmedizin Berlin, Berlin, Germany. 10. Department of Urology, Hospital Quiron Barcelona, Barcelona, Spain. 11. Department of Urology, Clinique Pasteur, Toulouse, France. 12. Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada. zorn.chumurology@gmail.com.
Abstract
OBJECTIVES: Previous analyses of the impact of median lobe presence on Greenlight photoselective vaporization of the prostate (PVP) outcomes were limited by their small sample size and the ability to adjust for important confounders. As such, we sought to investigate the impact of prostate median lobe presence on the operative outcomes of 180 W XPS GreenLight PVP using a large international database. METHODS: Data were obtained from the Global GreenLight Group (GGG) database which pools data of eight high-volume, experienced surgeons, from a total of seven international centers. All men with established benign prostatic hyperplasia who underwent GreenLight PVP using the XPS-180 W system between 2011 and 2019 were eligible for the study. Patients were assigned to two groups based on presence or absence of median lobes. Analyses were adjusted for patient age, prostate volume, body mass index, and American Society of Anesthesia (ASA) score. RESULTS: A total of 1650 men met the inclusion criteria. A median lobe was identified in 621 (37.6%) patients. Baseline prostate volume, patient age, and ASA score varied considerably between the two groups. In adjusted analyses, the operative and lasing time of patients with median lobes was 6.72 (95% CI 3.22-10.23; p < 0.01) minutes and 2.90 (95% CI 1.02-4.78; p < 0.01) minutes longer than the control group. Men with median lobes had similar postoperative functional outcomes to those without a median lobe except for a 1.59-point greater drop in the 12-month IPSS score compared to baseline (95% CI 0.11-3.08; p = 0.04) in the median lobe group, and a decrease in PVR after 6 months which was 46.51 ml (95% CI 4.65-88.36; p = 0.03) greater in patients with median lobes compared to men without median lobes. CONCLUSIONS: Our findings suggest that the presence of a median lobe has no clinically significant impact on procedural or postoperative outcomes for patients undergoing Greenlight PVP using the XPS-180 W system.
OBJECTIVES: Previous analyses of the impact of median lobe presence on Greenlight photoselective vaporization of the prostate (PVP) outcomes were limited by their small sample size and the ability to adjust for important confounders. As such, we sought to investigate the impact of prostate median lobe presence on the operative outcomes of 180 W XPS GreenLight PVP using a large international database. METHODS: Data were obtained from the Global GreenLight Group (GGG) database which pools data of eight high-volume, experienced surgeons, from a total of seven international centers. All men with established benign prostatic hyperplasia who underwent GreenLight PVP using the XPS-180 W system between 2011 and 2019 were eligible for the study. Patients were assigned to two groups based on presence or absence of median lobes. Analyses were adjusted for patient age, prostate volume, body mass index, and American Society of Anesthesia (ASA) score. RESULTS: A total of 1650 men met the inclusion criteria. A median lobe was identified in 621 (37.6%) patients. Baseline prostate volume, patient age, and ASA score varied considerably between the two groups. In adjusted analyses, the operative and lasing time of patients with median lobes was 6.72 (95% CI 3.22-10.23; p < 0.01) minutes and 2.90 (95% CI 1.02-4.78; p < 0.01) minutes longer than the control group. Men with median lobes had similar postoperative functional outcomes to those without a median lobe except for a 1.59-point greater drop in the 12-month IPSS score compared to baseline (95% CI 0.11-3.08; p = 0.04) in the median lobe group, and a decrease in PVR after 6 months which was 46.51 ml (95% CI 4.65-88.36; p = 0.03) greater in patients with median lobes compared to men without median lobes. CONCLUSIONS: Our findings suggest that the presence of a median lobe has no clinically significant impact on procedural or postoperative outcomes for patients undergoing Greenlight PVP using the XPS-180 W system.
Authors: Pierre-Alain Hueber; Marc Nicolas Bienz; Roger Valdivieso; Hugo Lavigueur-Blouin; Vincent Misrai; Matthew Rutman; Alexis E Te; Bilal Chughtai; Neil J Barber; Amr M Emara; Ravi Munver; Quoc-Dien Trinh; Kevin C Zorn Journal: J Urol Date: 2015-04-04 Impact factor: 7.450
Authors: Roger Valdivieso; Pierre-Alain Hueber; Malek Meskawi; Eric Belleville; Khaled Ajib; Franck Bruyere; Alexis E Te; Bilal Chughtai; Dean Elterman; Vincent Misrai; Kevin C Zorn Journal: BJU Int Date: 2018-04-23 Impact factor: 5.588
Authors: Malek Meskawi; Pierre-Alain Hueber; Roger Valdivieso; Pierre I Karakiewicz; Benjamin Pradere; Vincent Misrai; Bilal Chughtai; Kevin C Zorn Journal: World J Urol Date: 2018-11-26 Impact factor: 4.226
Authors: Michael M Lieber; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; Cynthia J Girman; Steven J Jacobsen Journal: J Urol Date: 2009-10-17 Impact factor: 7.450
Authors: Kyle W Law; Dean S Elterman; Hannes Cash; Enrique Rijo; Bilal Chughtai; Vincent Misrai; Kevin C Zorn Journal: Can J Urol Date: 2019-10 Impact factor: 1.344
Authors: Fady K Ghobrial; Ahmed Shoma; Ahmed M Elshal; Mahmoud Laymon; Nasr El-Tabey; Adel Nabeeh; Ahmed A Shokeir Journal: BJU Int Date: 2019-11-12 Impact factor: 5.588
Authors: Ahmed S Zakaria; Félix Couture; David-Dan Nguyen; Côme Tholomier; Hanna Shahine; Franziska Stolzenbach; Malek Meskawi; Pierre I Karakiewicz; Assaad El-Hakim; Kevin C Zorn Journal: World J Urol Date: 2020-10-27 Impact factor: 4.226